GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
The role of glucose-stimulated release of GLP-1 in the development of obesity and type 2 diabetes is unclear. We assessed GLP-1 response to oral glucose in a large study population of lean and obese men and women with normal and impaired glucose regulation. Circulating concentrations of glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with normal glucose tolerance (NGT) (n = 774), prediabetes (n = 525), or screen-detected type 2 diabetes (n = 163) who attended the Danish ADDITION-PRO study (n = 1,462). Compared with individuals with NGT, women with prediabetes or type 2 diabetes had 25% lower GLP-1 response to an OGTT, and both men and women with prediabetes or type 2 diabetes had 16-21% lower 120-min GLP-1 concentrations independent of age and obesity. Obese and overweight individuals had up to 20% reduced GLP-1 response to oral glucose compared with normal weight individuals independent of glucose tolerance status. Higher GLP-1 responses were associated with better insulin sensitivity and β-cell function, older age, and lesser degree of obesity. Our findings indicate that a reduction in GLP-1 response to oral glucose occurs prior to the development of type 2 diabetes and obesity, which can have consequences for early prevention strategies for diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [133]
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [133]
In the citing paper
“From a diabetes prevention perspective, the GLP-1-releasing effects of PUFAs could be particularly important, given that obese patients have lower GLP-1 responses to oral glucose than individuals of normal weight, irrespective of the glycemic status [52,53].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [52]
Citations
Cites
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“In type 2 diabetes, the incretin effect is impaired (2,3), but it remains controversial to what extent the defect is caused by a reduced release of incretin hormones and whether this reduction occurs prior to the development of type 2 diabetes.”
BackgroundAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Gender differences in insulin resistance, body composition, and energy balance
Geer, E. B., & Shen, W. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.02.002 · Cited by 913
Seltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883 · cited 4×
“These findings are in agreement with the glucoregulatory effects of GLP-1 (33,34) and with studies showing that infusion of the GLP-1 receptor antagonist exendin-(9-39) reduced first-phase insulin release and decreased insulin action in healthy individuals and in patients with type 2 diabetes (35,36).”
BackgroundMethodResultInfluentialNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“The incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide contribute to glucose-stimulated insulin release and therefore play important roles in maintaining normal glucose regulation (1).”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Validation of the insulin sensitivity index (ISI0,120): comparison with other measures
Gutt, M., Davis, C. L., Spitzer, S. B., Llabre, M. M., Kumar, M., Czarnecki, E. M., Schneiderman, N., Skyler, J. S., & Marks, J. B. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00116-3 · Cited by 474
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · cited 4×
“The role of age in the release of GLP-1 has not previously been clearly established (4,41).”
BackgroundSelf-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 1×
“However, as other studies have found similar elimination rates and gastric emptying rates of GLP-1 in individuals with and without diabetes (45,46), our findings of reduced GLP-1 response in prediabetes and diabetes are likely to reflect an impaired release of GLP-1.”
ResultSelf-citationVerdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 5×
“BMI has been inversely associated with GLP-1 response in a number of studies (7,11,14,15).”
BackgroundSelf-citationHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396
Attenuated GLP-1 secretion in obesity: cause or consequence
Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394
Vollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1124 · Cited by 356
Reduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Influence of gender and menopause on gastric emptying and motility
Hutson, W. R., Roehrkasse, R. L., & Wald, A. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90758-0 · Cited by 304
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 288
Færch, K., Borch-Johnsen, K., Holst, J. J., & Vaag, A. (2009) · Diabetologia · doi:10.1007/s00125-009-1443-3 · Cited by 252
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251 · cited 13×
“Fasting and 2-h insulin concentrations as well as total insulin responses during the OGTT were also higher in men and women with prediabetes or type 2 diabetes compared with NGT individuals (Table 2; Table 3; Fig.”
BackgroundMethodSelf-citationGRuttenfor the ADDITION Study Group, Lauritzen, T., Griffin, S., Borch-Johnsen, K., Wareham, N., & Wolffenbuttel, B. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801420 · Cited by 249
Impaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
Incretin Hormone and Insulin Responses to Oral Versus Intravenous Lipid Administration in Humans
Lindgren, O., Carr, R. D., Deacon, C. F., Holst, J. J., Pacini, G., Mari, A., & Ahrén, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0266 · Cited by 188
Migoya, E. M., Bergeron, R., Miller, J. L., Snyder, R. N. K., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.184 · Cited by 179
Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes
Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7743 · Cited by 164
Self-citationLaakso, M., Zilinskaite, J., Hansen, T. F., Boesgaard, T. W., Vänttinen, M., Stančáková, A., Jansson, P., Pellmé, F., Holst, J. J., Kuulasmaa, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0899-2 · Cited by 158
Færch, K., Vaag, A. A., Holst, J. J., Glümer, C., Pedersen, O. B., & Borch‐Johnsen, K. (2008) · Diabetologia · doi:10.1007/s00125-008-0951-x · Cited by 156
Vaag, A. A., Holst, J. J., Vølund, A., & Beck-Nielsen, H. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350425 · Cited by 154
Færch, K., Borch‐Johnsen, K., Vaag, A. A., Jørgensen, T., & Witte, D. R. (2010) · Diabetologia · doi:10.1007/s00125-010-1673-4 · Cited by 149
Iepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118 · cited 1×
“Since we found reduced endogenous GLP-1 levels and response in prediabetes, treatment with GLP-1 analogs could be relevant as part of a prevention strategy if weight loss attempts are unsuccessful, in agreement with recent findings from studies of obese individuals with prediabetes (50,51,53).”
ResultSelf-citationBak, M. J., Wewer Albrechtsen, N. J., Pedersen, J., Knop, F. K., Vilsbøll, T., Jørgensen, N. B., Hartmann, B., Deacon, C. F., Dragsted, L. O., & Holst, J. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12352 · Cited by 108
Rask, E., Olsson, T., Söderberg, S., Holst, J. J., Tura, A., Pacini, G., & Åhrén, B. (2004) · Metabolism · doi:10.1016/j.metabol.2003.11.011 · Cited by 99
Perreault, L., & Færch, K. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.10.008 · Cited by 95
Hjøllund, K. R., Deacon, C. F., & Holst, J. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2168-7 · Cited by 84
Hoist, J. J. (1983) · Diabetologia · doi:10.1007/bf00251825 · Cited by 77
Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle
Sjøberg, K. A., Holst, J. J., Rattigan, S., Richter, E. A., & Kiens, B. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00283.2013 · Cited by 69
Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
Torekov, S. S., Madsbad, S., & Holst, J. J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00860.x · Cited by 65
Zhang, F., Tang, X., Cao, H., Lü, Q., Li, N., Liu, Y., Zhang, X., Zhang, Y., Cao, M., Wan, J., et al. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4128 · Cited by 64
Matikainen, N., Bogl, L. H., Hakkarainen, A., Lundbom, J., Lundbom, N., Kaprio, J., Rissanen, A., Holst, J. J., & Pietiläinen, K. H. (2014) · Diabetes Care · doi:10.2337/dc13-1283 · Cited by 63 · cited 6×
“Radioimmunological determinations of total plasma GLP-1 concentration [intact GLP-1 plus the metabolite GLP-1(9-36)amide] were performed as described previously (23–25).”
BackgroundMethodResultSelf-citationJohansen, N. B., Hansen, A.-L. S., Jensen, T. M., Philipsen, A., Rasmussen, S. S., Jørgensen, M. E., Simmons, R. K., Lauritzen, T., Sandbæk, A., & Witte, D. R. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-1078 · Cited by 57
Alssema, M., Rijkelijkhuizen, J. M., Holst, J. J., Teerlink, T., Scheffer, P. G., Eekhoff, E. M. W., Gastaldelli, A., Mari, A., Hart, L. M., Nijpels, G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0487 · Cited by 56
GIP Contributes to Islet Trihormonal Abnormalities in Type 2 Diabetes
Chia, C. W., Odetunde, J. O., Kim, W., Carlson, O. D., Ferrucci, L., & Egan, J. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3994 · Cited by 51
Impact of Glucose Tolerance Status, Sex, and Body Size on Glucose Absorption Patterns During OGTTs
Færch, K., Pacini, G., Nolan, J. J., Hansen, T., Tura, A., & Vistisen, D. (2013) · Diabetes Care · doi:10.2337/dc13-0592 · Cited by 45
Idorn, T., Knop, F. K., Jørgensen, M. B., Christensen, M., Holst, J. J., Hornum, M., & Feldt-Rasmussen, B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3809 · Cited by 41
Gjesing, A. P., Ekstrøm, C. T., Eiberg, H., Urhammer, S. A., Holst, J. J., Pedersen, O. B., & Hansen, T. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2484-6 · Cited by 33
Sathananthan, M., Farrugia, L. P., Miles, J. M., Piccinini, F., Dalla Man, C., Zinsmeister, A. R., Cobelli, C., Rizza, R. A., & Vella, A. (2013) · Diabetes · doi:10.2337/db13-0140 · Cited by 28
Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes
Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., & Ehlers, M. R. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01388.x · Cited by 25
Nathanson, D., Zethelius, B., Berne, C., Holst, J. J., Sjöholm, Å., & Nyström, T. (2009) · Diabetologia · doi:10.1007/s00125-009-1596-0 · Cited by 24
Torekov, S. S., Ma, L., Grarup, N., Hartmann, B., Hainerová, I. A., Kielgast, U. L., Kissow, H., ROSENKILDE, M. M., Lebl, J., Witte, D. R., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2265-7 · Cited by 19
Torekov, S. S., Holst, J. J., & Ehlers, M. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12240 · Cited by 14
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“A study in w1,500 Danish subjects suggested that the GLP-1 response to oral glucose is reduced in patients with prediabetes or type-2 diabetes [262].”
BackgroundSelf-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Sex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Sex differences in type 2 diabetes
Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023) · Diabetologia · doi:10.1007/s00125-023-05891-x · Cited by 624
Metadata
- Authors
- Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., Holst, J. J., & Jørgensen, M. E.
- Affiliations
- Steno Diabetes Center, Gentofte, Denmark
- University of Copenhagen (DK)
- Danish Diabetes Academy (DK)
- Section for General Practice, Department of Public Health, Aarhus, Denmark
- Corresponding author
- Færch, Kristine
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-02-12
- Volume
- 64
- Issue
- 7
- Pages
- 2513-2525
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2081594150
- Cited by
- 321
- References
- 54
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 28 · 2022: 27 · 2021: 34 · 2020: 28 · 2019: 41 · 2018: 26 · 2017: 20 · 2016: 22 · 2015: 11
- FWCI
- 22.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Foundation
- Danish Centre for Evaluation and Health Technology Assessment
- Diabetes Fund of the National Board of Health
- Danish Medical Research Council
- Aarhus University Research Foundation
- European Foundation for the Study of Diabetes/Pfizer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes (74550801)
- National Health Services in the counties of Copenhagen, Aarhus, Ringkøbing, Ribe, and Southern Jutland in Denmark
- Danish Council for Strategic Research
- Danish Research Foundation for General Practice
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, glucose-stimulated insulin secretion, prediabetes, type 2 diabetes, obesity, sex differences, oral glucose tolerance test, insulin sensitivity, beta-cell function
- MeSH terms
- Age Factors, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin, Male, Middle Aged, Obesity, Prediabetic State, Sex Characteristics, Body Mass Index, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.